SBC-115337

Cat. No.:	HY-141714
CAS No.:	423148-46-3
Molecular Formula:	$C_{29}H_{19}N_3O_4$
Molecular Weight:	473.48
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 6.67 mg/mL (14.09 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1120 mL	10.5601 mL	21.1202 mL
	5 mM	0.4224 mL	2.1120 mL	4.2240 mL
	10 mM	0.2112 mL	1.0560 mL	2.1120 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC_{50} value of 0.5 μM[1][2].

IC_{50} & Target

IC50: 0.5 μM (PCSK9)[1]

In Vitro

The potent compound (SBC-115,337) shows an IC50 of 0.6 μM measured in an in vitro ELISA assay to monitor the effect of PCSK9 binding to the recombinant LDLR. SBC-115,337 at 1.2 μM induces more than tenfold upregulation of LDLR in HepG2 cells with respect to the control, increases uptake of fluorescently labeled DiI-LDL and loweres LDL-c levels in mice fed a high-fat diet[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Xu S, et al. Small molecules as inhibitors of PCSK9: Current status and future challenges. Eur J Med Chem. 2019;162:212-233.

[2]. Lavecchia A, et al. Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy. Future Med Chem. 2019;11(5):423-441.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA